INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 368 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2024. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $6,781,332 | – | 99,012 | – | 1.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 156,250 | $8,268,750 | 5.59% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 221,856 | $11,733,964 | 3.62% |
| Vahanian & Associates Financial Planning Inc. | 18,592 | $983,889 | 3.22% |
| Altium Capital Management LP | 100,000 | $5,292,000 | 2.69% |
| Bellevue Group AG | 3,342,236 | $176,871,129 | 2.35% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,036,948 | $54,875,288 | 2.30% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 140,366 | $7,428,169 | 2.12% |
| Nicholas Investment Partners, LP | 413,507 | $21,882,790 | 1.92% |
| TANG CAPITAL MANAGEMENT LLC | 240,000 | $12,700,800 | 1.84% |
| Octagon Capital Advisors LP | 220,953 | $11,692,833 | 1.82% |